Cullinan Therapeutics, Inc.
CGEM
$10.50
$0.302.94%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -51.05% | -45.44% | -35.05% | -9.28% | 8.07% |
| Total Depreciation and Amortization | 0.98% | -1.29% | -2.55% | -1.29% | 4.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 60.85% | 36.41% | 36.61% | 17.17% | -21.63% |
| Change in Net Operating Assets | 771.63% | 330.89% | 150.14% | -14.75% | 78.06% |
| Cash from Operations | -37.43% | -35.26% | -23.61% | -8.21% | 10.15% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 272.21% | 177.03% | -434.45% | -478.50% | -132.95% |
| Cash from Investing | 272.17% | 177.03% | -434.94% | -480.70% | -127.69% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.27% | -98.53% | 573.69% | 595.26% | 592.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 82.70% | -12,455.56% | -- | 86.64% |
| Cash from Financing | -99.26% | -98.76% | 561.98% | 553.21% | 3,389.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -96.64% | -57.39% | 105.07% | 73.27% | 120.94% |